Combination therapy as a tool to prevent emergence of bacterial resistance. - Wikidata - wikimedia - TriplyDB

Combination therapy as a tool to prevent emergence of bacterial resistance.

Combination therapy as a tool to prevent emergence of bacterial resistance.

http://www.wikidata.org/entity/Q33961767

about

Can we prevent antimicrobial resistance by using antimicrobials better?Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis.Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.Combination therapy for treatment of infections with gram-negative bacteria.Drug resistance pattern of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients at Isfahan AL Zahra hospital, Iran (2009-2010).Dynamics of symbiont-mediated antibiotic production reveal efficient long-term protection for beewolf offspring.Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?Bactericidal antibiotic-phytochemical combinations against methicillin resistant Staphylococcus aureus.Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii.Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment Monotherapy or combination therapy? The Pseudomonas aeruginosa conundrum.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria.Antibiotic-resistant Pseudomonas aeruginosa: focus on care in patients receiving assisted ventilation.In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee.Treatment of multidrug-resistant pseudomonas aeruginosa using extended-infusion antimicrobial regimens.Management of aminoglycosides in the intensive care unit.Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates.In vitro synergy and selection of resistance by fluoroquinolones plus amikacin or beta-lactams against extended-spectrum beta-lactamase-producing Escherichia coli.The antimicrobial effect of blue light: What are behind?In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

P2860

Q26829707-17EFD0FC-D190-44C0-A241-D43D123A9E02 Q28484482-ADD44962-DE47-4D07-9728-5C8586CC2CFD Q30756968-167ABE6C-35DF-4BBC-95C0-85E3A9720717 Q31143077-11EBAE55-AEAD-47CA-B081-143C194D59D4 Q34407557-60AF49FC-07A8-436A-8792-CEA49067E05D Q35685688-4D21C619-A160-4318-AC46-0F0F7CBB10B2 Q36156077-26BF7315-E928-4DC0-8571-1A697422F322 Q36211412-F27C357C-FB73-4AA0-BAB5-3B84CFE20F0B Q36689853-56EF80A1-497B-4E1C-BB0E-155A013334B2 Q36853968-CE4798A0-55BF-4CF3-BAD3-181629EB273B Q37159988-E0780E5C-83F4-4A92-9C92-3690DDDD2317 Q37187728-3BF680E9-BCCF-49A8-9A0D-1E9EAE4CC231 Q37656663-46709A47-B6CB-40A7-82AF-A748F51C790D Q37933370-AB168AF6-F7A1-4049-9B86-A8C5AD880C6F Q37949391-FEB364E0-13C0-42FB-90E8-A348DABC2384 Q38199180-52C879DF-E0FE-4806-A713-33087B20F89C Q38210320-CDE05E40-D3BA-4203-95C1-7609FD23C407 Q39677063-709D4CD9-6A6C-4A89-A61F-C8391353AAEF Q40335979-7CAB6A43-9837-4C74-B3A6-E2C7E0982FEB Q41564878-D3B2110E-6CA7-451A-9F2E-87FD728845BD Q42908869-D8BF3232-623E-4D3B-BB07-046094DBB162 Q43787799-DC27DEEE-393B-48C7-AA84-DCCFA49CFF85 Q46436165-E95CD625-76BA-46C4-93B7-856A8529CE52 Q47156138-AB0C38DC-512D-4FC6-8C82-7F86D6BF5FCC Q51018579-FD7674CB-4929-4472-911A-F76014871E0E

P2860

Combination therapy as a tool to prevent emergence of bacterial resistance.

http://www.wikidata.org/entity/Q33961767

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Combination therapy as a tool to prevent emergence of bacterial resistance.

@ast

Combination therapy as a tool to prevent emergence of bacterial resistance.

@en

type

label

Combination therapy as a tool to prevent emergence of bacterial resistance.

@ast

Combination therapy as a tool to prevent emergence of bacterial resistance.

@en

prefLabel

Combination therapy as a tool to prevent emergence of bacterial resistance.

@ast

Combination therapy as a tool to prevent emergence of bacterial resistance.

@en

P1433

Q33961767-4F1E15C6-4963-4F37-8634-A65BCC3827AB

P1476

Q33961767-308B6542-86D2-42C3-BF4E-EAA28F84DF04

P2093

Q33961767-220A55FC-A706-4BA1-99A3-42D3E8A7F372

P2860

Q33961767-237818C3-31E4-4794-BF23-F0FC561B2ABF

Q33961767-264F7C5D-5613-4A87-9F5F-2C349F647504

Q33961767-282FCFF3-E792-4D16-8BC9-2EDFC82C3456

Q33961767-54076A63-3351-464A-B37B-552740CE3261

Q33961767-6828C692-816E-4DF7-8C6D-5FB8160389E1

Q33961767-78871EDB-6F64-42B3-9B7A-86C815110769

Q33961767-9D086DA2-E979-42A6-9FB3-A62075A7CE52

P2888

Q33961767-EC2B359A-B05B-4BA3-949F-A3A0ECA9172B

P304

Q33961767-A2C3AD93-3249-4768-8C97-B70907EA4F42

P31

Q33961767-072E9E6C-40F3-45D9-8861-F78FC4604BC5

P356

Q33961767-3DD8FEBF-D608-4A75-9ED1-BA354C05D16D

P478

Q33961767-1A1961D0-78C0-42F1-980F-0371E4A41975

P577

Q33961767-207C55FB-4713-4E60-95C2-CDF6DEBEE963

P6179

Q33961767-B058FCA3-DB6A-49A9-9D7B-2B41A0AEA3BC

P698

Q33961767-B7DB1741-889C-48D1-88AC-4E5BB343D1A1

P356

P1433

P1476

Combination therapy as a tool to prevent emergence of bacterial resistance.

@en

P2093

Mouton JW

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model.

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.

Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

Two compartment kinetic model with multiple artificial capillary units.

Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.

P2888

P304

S24-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF02561666

http://www.w3.org/2001/XMLSchema#string

P478

27 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P577

1999-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1028679003

http://www.w3.org/2001/XMLSchema#string

P698

10885823

http://www.w3.org/2001/XMLSchema#string